Shares of China Cord Blood Corp. (NYSE:CO) saw strong trading volume on Monday . 69,671 shares were traded during trading, an increase of 24% from the previous session’s volume of 56,190 shares.The stock last traded at $5.25 and had previously closed at $5.21.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research upgraded China Cord Blood Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. TheStreet cut China Cord Blood Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $6.75.

The firm has a market capitalization of $421.24 million and a price-to-earnings ratio of 28.13. The company has a 50 day moving average of $5.36 and a 200-day moving average of $5.85.

China Cord Blood Corp. (NYSE:CO) last announced its earnings results on Monday, August 22nd. The company reported $0.03 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.03. The company earned $26 million during the quarter, compared to the consensus estimate of $26.23 million. Equities analysts forecast that China Cord Blood Corp. will post $0.17 EPS for the current fiscal year.

China Cord Blood Corporation is principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. The Company provides cord blood testing, processing and storage services under the direction of subscribers. The Company also preserves cord blood units donated by the public, provides matching services on such donated units and delivers matching units to patients in need of transplants.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.